Study Supports FDA Advisory Committee Conflict-Of-Interest Waivers
This article was originally published in The Gray Sheet
Executive Summary
Constructing FDA advisory committees free from any conflicts of interest would be expensive and time-consuming and would likely exclude many of the most highly qualified candidates, according to an analysis commissioned by the agency
You may also be interested in...
FDA Proposes Changes To Advisory Committee Voting Procedures
FDA is proposing that members of its advisory committees vote on issues simultaneously, rather than sequentially, to avoid influencing each other
Draft Conflict-Of-Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and/or participate in meetings would be curtailed by a revised conflict-of-interest policy, FDA said
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”